Cargando…
Use of Neuroenhancement Drugs: Prevalence, Frequency and Use Expectations in Switzerland
Objective: The present study investigates the use expectations, prevalence and frequency of neuroenhancement drug (ND) use among the Swiss male population, separating college students from others. Methods: Young Swiss men were invited to participate in the Cohort Study on Substance Use Risk Factors....
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987019/ https://www.ncbi.nlm.nih.gov/pubmed/24625621 http://dx.doi.org/10.3390/ijerph110303032 |
_version_ | 1782311814924599296 |
---|---|
author | Deline, Stéphane Baggio, Stéphanie Studer, Joseph N’Goran, Alexandra A. Dupuis, Marc Henchoz, Yves Mohler-Kuo, Meichun Daeppen, Jean-Bernard Gmel, Gerhard |
author_facet | Deline, Stéphane Baggio, Stéphanie Studer, Joseph N’Goran, Alexandra A. Dupuis, Marc Henchoz, Yves Mohler-Kuo, Meichun Daeppen, Jean-Bernard Gmel, Gerhard |
author_sort | Deline, Stéphane |
collection | PubMed |
description | Objective: The present study investigates the use expectations, prevalence and frequency of neuroenhancement drug (ND) use among the Swiss male population, separating college students from others. Methods: Young Swiss men were invited to participate in the Cohort Study on Substance Use Risk Factors. A total of 5,967 participants responded to questions on six types of NDs (wakefulness medication, antidepressants, Alzheimer’s disease medication, Parkinson’s disease medication, attention deficit-hyperactivity disorder (ADHD) medication, and beta-blockers). The frequency of use depending on five expectations (to enhance wakefulness, attention, memory, concentration and stress reduction) was analyzed for a twelve-month period. Results: (1) About 3% of the sample indicated use of at least one ND; (2) ADHD medication was the most prevalent; (3) The type of ND preferred differed depending on academic status (4). Quantitatively, over the year, college student users used ND much less frequently than other users. Conclusions: Prevalence of ND use is low in Switzerland relative to other countries such as the United States. Patterns of ND use differed depending on academic status, suggesting that while college student ND users tended to do so rarely (probably to enhance cognitive abilities for exams), non-college male users used other NDs more frequently (probably to “get high”). |
format | Online Article Text |
id | pubmed-3987019 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-39870192014-04-15 Use of Neuroenhancement Drugs: Prevalence, Frequency and Use Expectations in Switzerland Deline, Stéphane Baggio, Stéphanie Studer, Joseph N’Goran, Alexandra A. Dupuis, Marc Henchoz, Yves Mohler-Kuo, Meichun Daeppen, Jean-Bernard Gmel, Gerhard Int J Environ Res Public Health Article Objective: The present study investigates the use expectations, prevalence and frequency of neuroenhancement drug (ND) use among the Swiss male population, separating college students from others. Methods: Young Swiss men were invited to participate in the Cohort Study on Substance Use Risk Factors. A total of 5,967 participants responded to questions on six types of NDs (wakefulness medication, antidepressants, Alzheimer’s disease medication, Parkinson’s disease medication, attention deficit-hyperactivity disorder (ADHD) medication, and beta-blockers). The frequency of use depending on five expectations (to enhance wakefulness, attention, memory, concentration and stress reduction) was analyzed for a twelve-month period. Results: (1) About 3% of the sample indicated use of at least one ND; (2) ADHD medication was the most prevalent; (3) The type of ND preferred differed depending on academic status (4). Quantitatively, over the year, college student users used ND much less frequently than other users. Conclusions: Prevalence of ND use is low in Switzerland relative to other countries such as the United States. Patterns of ND use differed depending on academic status, suggesting that while college student ND users tended to do so rarely (probably to enhance cognitive abilities for exams), non-college male users used other NDs more frequently (probably to “get high”). MDPI 2014-03-12 2014-03 /pmc/articles/PMC3987019/ /pubmed/24625621 http://dx.doi.org/10.3390/ijerph110303032 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Deline, Stéphane Baggio, Stéphanie Studer, Joseph N’Goran, Alexandra A. Dupuis, Marc Henchoz, Yves Mohler-Kuo, Meichun Daeppen, Jean-Bernard Gmel, Gerhard Use of Neuroenhancement Drugs: Prevalence, Frequency and Use Expectations in Switzerland |
title | Use of Neuroenhancement Drugs: Prevalence, Frequency and Use Expectations in Switzerland |
title_full | Use of Neuroenhancement Drugs: Prevalence, Frequency and Use Expectations in Switzerland |
title_fullStr | Use of Neuroenhancement Drugs: Prevalence, Frequency and Use Expectations in Switzerland |
title_full_unstemmed | Use of Neuroenhancement Drugs: Prevalence, Frequency and Use Expectations in Switzerland |
title_short | Use of Neuroenhancement Drugs: Prevalence, Frequency and Use Expectations in Switzerland |
title_sort | use of neuroenhancement drugs: prevalence, frequency and use expectations in switzerland |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987019/ https://www.ncbi.nlm.nih.gov/pubmed/24625621 http://dx.doi.org/10.3390/ijerph110303032 |
work_keys_str_mv | AT delinestephane useofneuroenhancementdrugsprevalencefrequencyanduseexpectationsinswitzerland AT baggiostephanie useofneuroenhancementdrugsprevalencefrequencyanduseexpectationsinswitzerland AT studerjoseph useofneuroenhancementdrugsprevalencefrequencyanduseexpectationsinswitzerland AT ngoranalexandraa useofneuroenhancementdrugsprevalencefrequencyanduseexpectationsinswitzerland AT dupuismarc useofneuroenhancementdrugsprevalencefrequencyanduseexpectationsinswitzerland AT henchozyves useofneuroenhancementdrugsprevalencefrequencyanduseexpectationsinswitzerland AT mohlerkuomeichun useofneuroenhancementdrugsprevalencefrequencyanduseexpectationsinswitzerland AT daeppenjeanbernard useofneuroenhancementdrugsprevalencefrequencyanduseexpectationsinswitzerland AT gmelgerhard useofneuroenhancementdrugsprevalencefrequencyanduseexpectationsinswitzerland |